Otsuka Pharmaceuticals and Click Therapeutics announced that Rejoyn, a smartphone-based prescription digital therapeutic for major depressive disorder (MDD), scored FDA clearance to be used as an adjunct to clinician-managed care.
Rejoyn is a six-week remote treatment program to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional training...
Global healthcare company AmerisourceBergen has announced a strategic partnership with business-to-business telehealth provider SteadyMD, beginning with the companies cocreating and piloting a telehealth offering for independent community pharmacies dubbed Test to Treat.
The Test to Treat model allows individuals to be tested for an illness or condition at an independent pharmacy and then consult...
U.K.-based Ultromics announced it received FDA Breakthrough Device Designation for an AI tool that aims to detect cardiac amyloidosis.
The platform, called EchoGo Amyloidosis, analyzes echocardiograms to find signs of the condition, where the protein amyloid builds up in the heart and limits function. Though the designation isn’t a marketing approval from the FDA, it aims to accelerate review of...
At the tail end of 2022, Click Therapeutics announced it was expanding its partnership with Boehringer Ingelheim focused on developing prescription digital therapeutics for patients with schizophrenia.
Pharma partnerships aren't new for digital health players, or for Click, which has several products in its development pipeline. The company's chief strategy officer, Austin Speier, said Click...
Pharma company Boehringer Ingelheim and Click Therapeutics announced an expanded partnership to develop and commercialize another prescription digital therapeutic for patients with schizophrenia.
The deal will net Click up to $460 million, plus tiered royalties. It builds on an earlier collaboration announced in 2020 that developed CT-155, an initial therapeutic for schizophrenia.
The companies...
Headspace Health confirmed it has laid off 50 workers, or about 4% of its workforce.
First reported by Bloomberg, the cuts at the meditation and mental health company are the latest in a spate of layoffs at digital health and health tech companies this year.
Calm, another meditation app that has been expanding with clinical mental health offerings, laid off 20% of its staff in August.
Click...
Clinical trial tech company Unlearn scored $50 million in a Series B financing round led by Insight Partners.
Other participants in the round include Radical Ventures, 8VC, DCVC, DCVC Bio and Mubadala Capital Ventures. According to Crunchbase, Unlearn's total raise now totals nearly $70 million.
Unlearn uses a machine learning model to create digital twins of randomized controlled trial...
Digital therapeutic Click Therapeutics has tapped AI-backed neurological disease diagnostic Altoida in to help it incorporate more sensitive measures of cognition into their DTx research.
The partnership will bring Altoida's cognition measuring capabilities into Click's clinical trials.
“Partnering with Altoida allows us to leverage their AI-driven augmented reality technology to help us better...
This morning prescription digital therapeutic company Click Therapeutic announced a $52 million Series B funding round. H.I.G. BioHealth Partners and Accelmed Partners ll led the round, with participation from Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures and RdigetopHealth.
This news comes over a year after the company inked a $500 million-plus deal with...
It’s no secret that Click Therapeutics is on a roll with pharma partnerships. The mental health-focused digital therapeutic company made headlines this week when it announced a new clinical trial with Japanese pharma company Otsuka, based on a deal made in 2019.
But this isn't the only deal the New York-based company worked on with the life science industry. In September, the company signed a $...
_1e92b.jpg "A woman holding a smartphone looking out a window.")
_43ae6.jpg)
